Celyad Oncology SA (EBR:CYAD)

Celyad Oncology Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 9, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	15	8	29	16	11	79
Market Cap Growth	-33.95%	-74.20%	82.56%	41.33%	-85.61%	-13.96%
Enterprise Value	13	8	24	12	-1	76
Last Close Price	0.32	0.17	0.71	0.39	0.51	3.52
PE Ratio	18.00	9.17	-	-	-	-
PS Ratio	690.61	362.36	158.59	158.40	-	-
PB Ratio	5.95	3.12	57.72	2.56	2.65	1.82
P/TBV Ratio	5.99	3.14	60.45	2.58	2.96	10.00
EV/Sales Ratio	-	364.31	130.42	114.87	-	-
EV/EBITDA Ratio	-	7.19	-	-	-	-
EV/EBIT Ratio	-	8.68	-	-	-	-
Debt / Equity Ratio	-	-	1.77	0.17	0.06	0.06
Net Debt / Equity Ratio	-0.70	-0.70	-6.45	-0.94	-2.82	-0.63
Net Debt / EBITDA Ratio	-1.60	-1.60	0.58	0.66	0.49	1.03
Net Debt / FCF Ratio	0.25	0.25	0.58	0.37	0.43	1.01
Asset Turnover	0.00	0.00	0.01	0.01	-	-
Quick Ratio	1.35	1.35	1.79	3.34	1.31	2.34
Current Ratio	1.92	1.92	2.29	3.79	1.42	2.48
Return on Equity (ROE)	56.33%	56.33%	-170.92%	-159.08%	-170.72%	-71.05%
Return on Assets (ROA)	7.74%	7.74%	-27.99%	-33.14%	-31.92%	-23.32%
Return on Capital Employed (ROCE)	35.50%	35.50%	-82.90%	-71.50%	-273.90%	-41.20%
Earnings Yield	5.72%	10.91%	-19.74%	-52.29%	-358.06%	-33.38%
FCF Yield	-	-90.68%	-19.26%	-99.65%	-246.08%	-33.97%
Buyback Yield / Dilution	-11.30%	-11.30%	-61.06%	-13.84%	-44.80%	-11.92%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.